NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 980 DKK | +0.62% |
|
-2.36% | +40.51% |
| Sales 2024 * | 292B 42.4B | Sales 2025 * | 353B 51.25B | Capitalization | 4,320B 628B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.13B | Net income 2025 * | 128B 18.61B | EV / Sales 2024 * | 14.9 x |
| Net Debt 2024 * | 22.53B 3.27B | Net cash position 2025 * | 5.57B 810M | EV / Sales 2025 * | 12.2 x |
| P/E ratio 2024 * |
42.1
x | P/E ratio 2025 * |
34.1
x | Employees | 66,015 |
| Yield 2024 * |
1.21% | Yield 2025 * |
1.49% | Free-Float | 70.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | +0.82% | ||
| 1 week | -2.07% | ||
| Current month | -2.17% | ||
| 1 month | -0.47% | ||
| 3 months | +12.87% | ||
| 6 months | +36.64% | ||
| Current year | +40.93% |
1 week
947.50
1 013.40
1 month
947.501 033.20
Current year
688.801 033.20
1 year
504.401 033.20
3 years
267.351 033.20
5 years
156.001 033.20
10 years
109.101 033.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 218 M€ | +17.17% | ||
| 10.45% | 4 M€ | +16.07% | ||
| 5.40% | 21 M€ | +10.60% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-08 | 981.3 | +0.75% | 336 497 |
| 24-07-05 | 974 | +0.41% | 1,698,852 |
| 24-07-04 | 970 | +0.26% | 1,603,895 |
| 24-07-03 | 967.5 | -2.62% | 2,411,588 |
| 24-07-02 | 993.5 | -1.10% | 2,906,007 |
Delayed Quote Nasdaq Copenhagen, July 08, 2024 at 04:23 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.93% | 627B | |
| +56.89% | 823B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +14.09% | 239B | |
| +14.21% | 220B | |
| -0.41% | 219B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- NOVO B Stock